Recent Advances in Cervical Cancer Treatment
EP. 1: Understanding the Biology and Staging of Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.
EP. 2: Role of HPV Vaccination and Screening to Prevent Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.
EP. 3: What is the Current Role of Biomarker Testing in Cervical Cancer?
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.
EP. 4: Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.
EP. 5: Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.
EP. 6: Ongoing Clinical Trials in Locally Advanced Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.
EP. 7: Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.
EP. 8: KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.
EP. 9: Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu Tewari, MD,Premal H. Thaker, MD, MS Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
EP. 10: Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
EP. 11: Second-Line Immune Checkpoint Inhibition in Metastatic Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
EP. 12: Metastatic Cervical Cancer: Moving Immune Checkpoint Inhibition to the Front Line
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
EP. 13: Tisotumab Vedotin: A Second-Line ADC Approval in Metastatic Cervical Cancer
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
EP. 14: Metastatic Cervical Cancer: ADC Adverse Event Management
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.
EP. 15: Metastatic Cervical Cancer: Practical Considerations for Tisotumab Vedotin Use
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.
EP. 16: Cervical Cancer Management: Looking Toward the Future of Care
ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.
